{"id":"W4385612755","doi":"10.1016/j.jaad.2023.07.1024","title":"Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up","year":2023,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":46,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen's University; Probity Medical Research","funders":"Sanofi Genzyme; Celltrion; Eisai; Bristol-Myers Squibb; Samsung; AbbVie Canada; Coherus Biosciences; Mitsubishi Tanabe Pharma Corporation; Pfizer; Incyte; Regeneron Pharmaceuticals; Mylan; Castle Biosciences; Dermira; Sun Pharma; Helsinn; Celgene; AbbVie; Sanofi; Amgen; Meiji Seika Pharma; EMD Serono; Galderma; Ortho Dermatologics; Eli Lilly and Company; GlaxoSmithKline","keywords":"Medicine; Psoriasis Area and Severity Index; Psoriasis; Discontinuation; Adverse effect; Dermatology Life Quality Index; Internal medicine; Placebo; Randomized controlled trial; Severity of illness; Interim analysis; Surgery; Dermatology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000345276,0.0002066194,0.001677782,0.000378593,0.00009535924,0.000004539339,0.0008959574,0.0001728309,0.0000143929],"category_scores_gemma":[0.0001889224,0.0001119842,0.0005666591,0.0009232324,0.0005086872,0.00004920975,0.0002563948,0.0001518041,0.00000157228],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004462028,"about_ca_system_score_gemma":0.0001144266,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009706843,"about_ca_topic_score_gemma":0.00002954515,"domain_scores_codex":[0.9976473,0.0006114265,0.001179139,0.0002106718,0.0001117742,0.0002396706],"domain_scores_gemma":[0.9959247,0.001400018,0.002151303,0.0003602324,0.0001269829,0.00003681439],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.444227,0.002935236,0.02946407,0.0001637996,0.04089943,0.00001359512,0.01278491,0.001749746,0.2905644,0.0003832122,0.0030556,0.1737589],"study_design_scores_gemma":[0.1010024,0.00585042,0.5284635,0.0003857406,0.01439029,0.0003659896,0.002377153,0.0001190269,0.3453104,0.00012873,0.001254799,0.0003515779],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9949655,0.001151583,0.0000958583,0.002123611,0.0005949074,0.0008375547,0.0002211537,0.000003572902,0.000006272431],"genre_scores_gemma":[0.9980457,0.001553948,0.00009254782,0.00009832151,0.00002281225,0.00001941011,0.000006971844,0.00001628693,0.0001439418],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4989994,"threshold_uncertainty_score":0.4566584,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05163728112051134,"score_gpt":0.3408411507546446,"score_spread":0.2892038696341332,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}